Twelve Kits, Fourteen Patients

Allocation: the four sickest get atropine + pralidoxime first; the miosis-only group gets none; the asymptomatic group gets none.

• The three in respiratory distress with secretions and fasciculations are the true emergencies. They get atropine and pralidoxime immediately, repeated at 5–10 min intervals until secretions dry and breathing improves. Fasciculations indicate significant absorbed dose.
• The seizing patient gets atropine + pralidoxime plus a benzodiazepine. Seizures in nerve agent poisoning reflect severe CNS cholinergic excess and are the strongest predictor of poor outcome - do not delay for a second set of vitals.
• The five with miosis only are the allocation decision the exam is testing. Miosis is a local ocular effect of vapor and is not an indication for systemic atropine. These patients have normal breathing and normal heart rate; atropine would give them tachycardia, dry mouth, and delirium for no benefit. They need decontamination, observation, and a repeat respiratory exam.
• The five asymptomatic need no antidote, but they do need 12–24 hours of observation: vapor exposure can worsen over hours, and hypoxia can make a deteriorating patient look calm. Reassess at intervals.

That leaves kits in reserve for deterioration or for a patient who arrives later - deliberately, not accidentally. The toddler is asymptomatic and gets nothing; one of the two pediatric autoinjectors stays available.

Secondary contamination: secretions and vomit are contaminated. Staff in appropriate PPE, decon before transport, and no eating or bare-hand contact with patients.

Titrate to the airway, not to the eyes and not to the heart rate.

Endpoints that tell you the dose is working:

• Drying of bronchial secretions and resolution of bronchorrhea
• Relief of bronchospasm and improved oxygenation
• Resolution of bradycardia and of the cholinergic signs driving it

Endpoints that mislead:

• Pupil size - miosis can persist long after systemic toxicity is controlled, and chasing it produces atropine poisoning.
• Heart rate alone - tachycardia is a side effect you will produce; it is not the target and it is not a reason to withhold the next dose in a patient who is still drowning in secretions.
• Repeat dosing every 5–10 min. Large total doses are sometimes required, and the autoinjector supply is not the ceiling on the dose - it is the ceiling on your current stock, which is why the hospital must be told what you have given and what you are out of.

Why pralidoxime still matters: atropine is purely a competitive antagonist at muscarinic receptors. It does nothing at the neuromuscular junction, so fasciculations, weakness, and the coming respiratory muscle paralysis are untouched. Pralidoxime reactivates the inhibited acetylcholinesterase, but only before the enzyme–agent complex "ages" and becomes permanently inactivated - the window is hours, and it is shorter for some agents than others. Give it early, alongside atropine, and do not withhold it because the patient is already improving on atropine.

Oxygen first: atropine given to a hypoxic patient can precipitate arrhythmias. Oxygenate while you are drawing up.

Seizing patient:

• Benzodiazepine first - diazepam is what stands between the seizure and anoxic brain injury. Do not wait for a physician to arrive.
• Support oxygenation and ventilation. You have no ventilator, so this is a bag-valve-mask problem until the ambulance arrives, and it needs a second provider dedicated to it.
• If intubation becomes necessary, avoid succinylcholine. Acetylcholinesterase inhibition means plasma cholinesterase is also inhibited, so succinylcholine's breakdown is prolonged and paralysis can last far longer than expected. Use a non-depolarizing agent if you have one, or manage with BVM and a rescue airway.
• Continue atropine to effect and give pralidoxime early.

Toddler (11 kg) who now becomes symptomatic:

• Pediatric atropine dosing is weight-based, roughly 0.05 mg/kg - about 0.55 mg for this child. The 0.5 mg pediatric autoinjector is the right match; use it rather than an adult 2 mg injector if the pediatric device is available.
• If the only option were an adult autoinjector, the calculus changes: an antidote dose that is too large is still preferable to untreated nerve agent poisoning in a child with secretions and respiratory compromise. Document the reasoning.
• Pralidoxime dosing is also weight-based; if only adult 600 mg kits exist, that is a clinical decision for the receiving physician and should be communicated in the hand-off.

Hand-off: say aloud, to the receiving clinician, every dose and time - atropine, pralidoxime, diazepam - plus the suspected agent class. The single most common failure at the hospital door is a casualty arriving with a vague history of "some antidote."